Vimarsana
Biggest News Aggregation in the World

Page 39 - Genetic Technologies News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Genetic Technologies. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Genetic Technologies Today - Breaking & Trending Today

Supermarket lends voice to campaign opposed to deregulation of gene editing in the UK - Vimarsana News

Supermarket lends voice to campaign opposed to deregulation of gene editing in the UK

Supermarket lends voice to campaign opposed to deregulation of gene editing in the UK Leading supermarket chain, Co-op, has expressed caution over the UK government’s review into the future legislative approach to gene editing of crops and livestock in England. The Consultation on the Regulation of Genetic Technologies was launched by the UK's Department for the Environment, Food and Rural Affairs (Defra) on January 7 and will run until March 17, 2021. EU legislation controlling the use of GMOs was retained in the UK at the end of the transition period, after Dec...

BLUE Hit By SCD Trial Blues, CRTX Plunges On Partial Hold, SESN To Face FDA In August - Vimarsana News

BLUE Hit By SCD Trial Blues, CRTX Plunges On Partial Hold, SESN To Face FDA In August

(1) BASEL (dpa-AFX) - Today's Daily Dose brings you news about temporary suspension of bluebird bio's gene therapy trials in sickle cell disease, Sesen Bio's regulatory catalyst for this year, partial hold on Cortexyme's open-label extension phase of its ongoing phase II/III study of Atuzaginstat for Alzheimer's disease, and expanded FDA approval of Novartis' Entresto. Read on. 1. Sickle Cell Disease Trial Blues For bluebird bio Shares of bluebird bio Inc. (BLUE) slumped to a 5-year low on Tuesday as the company's LentiGlobin gene therapy trials for sickle cell disease were temporarily suspen...

AGTC Sheds Light On Achromatopsia Trials, Eli Lilly, VIR And GSK Team Up, CVM Turns Head As It Awaits Data - Vimarsana News

AGTC Sheds Light On Achromatopsia Trials, Eli Lilly, VIR And GSK Team Up, CVM Turns Head As It Awaits Data

(3) LONDON (dpa-AFX) - Today's Daily Dose brings you news about Applied Genetic's Achromatopsia trial results; the deadlock in AstraZeneca vaccine supply in EU; partnership of Lilly, Vir Biotech and GlaxoSmithKline in fighting COVID-19; and ZymeWork's progress with ZW49 study. Read on. 1. Applied Genetic Throws Light on Achromatopsia Trials Applied Genetic Technologies Corp.'s (AGTC) phase I/II clinical trials evaluating AAV gene therapy product candidates in patients with achromatopsia caused by CNGB3 or CNGA3 mutations, dubbed ACHMB3 and ACHMA3 trials, have provided for the first time quan...

Genetic Technologies Provides Update on its COVID-19 Disease Severity Risk Test and Expansion into Germline Testing - Vimarsana News

Genetic Technologies Provides Update on its COVID-19 Disease Severity Risk Test and Expansion into Germline Testing

News Category Global Banking & Finance Reviews Genetic Technologies Provides Update on its COVID-19 Disease Severity Risk Test and Expansion into Germline Testing Genetic Technologies Provides Update on its COVID-19 Disease Severity Risk Test and Expansion into Germline Testing MELBOURNE, Australia, Jan. 21, 2021 — Molecular diagnostics company Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”), provides the following update to the market on further development on the COVID-19 serious disease risk Polygenic Risk Score Test (COVID-19 PRS Test) and expansion of the Companyâ€...

Genetic Technologies Announces $6.56 Million Registered Direct Offering - Vimarsana News

Genetic Technologies Announces $6.56 Million Registered Direct Offering

Press release content from Globe Newswire. The AP news staff was not involved in its creation.

Source: apnews.com